对STK19的药理定位抑制了瘤性NRAS驱动的黑色素形成
Chengqian Yin1, Bo Zhu1, Ting Zhang2
1Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Cell
|February 5, 2019
概括
研究人员发现STK19是黑色素瘤中的新型NRAS激活剂. 用ZT-12-037-01向STK19为NRAS突变黑色素瘤提供了一个有前途的治疗策略.
科学领域:
- 癌症学
- 分子生物学
- 生物化学
背景情况:
- 激活NRAS突变导致20%-30%的黑色素瘤,但有效的治疗仍然难以捉摸.
- 与BRAF不同的是,NRAS的致癌驱动因素缺乏有针对性的治疗策略.
- 了解NRAS激活机制对于开发新的黑色素瘤治疗至关重要.
研究的目的:
- 在黑色素瘤中发现新型NRAS激活剂.
- 研究STK19在NRAS介导的黑色素形成中的作用.
- 开发和评估针对NRAS突变黑色素瘤的STK19抑制剂.
主要方法:
- 通过生物化学测定确定STK19作为NRAS激活剂.
- 对NRAS的STK19化及其下游效应的描述.
- 使用STK19 D89N knockin模型和STK19抑制剂ZT-12-037-01的体内研究.
主要成果:
- 确定STK19是一种激活NRAS的新型血清蛋白/三氨酸激酶.
- STK19增强了NRAS与下游效应体的结合,促进了恶性转变.
- 在25%的黑色素瘤中发现的STK19 D89N功能增强突变增强了NRAS活性.
- 通过ZT-12-037-01抑制STK19,在体外和体内有效地阻断黑色素瘤的生长.
结论:
- 在黑色素瘤中,STK19是瘤性NRAS的关键激活剂.
- 在一些黑色素瘤中,STK19 D89N是显著的致癌因子.
- 用像ZT-12-037-01这样的抑制剂向STK19为NRAS突变黑色素瘤提供了可行的治疗策略.
相关概念视频
00:46Feedback Inhibition
57.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
01:33Cancer-Critical Genes I: Proto-oncogenes
11.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.5K
01:30Enzyme Inhibition
92.2K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.2K
01:27ATP Driven Pumps I: An Overview
9.8K
ATP-driven pumps, also known as transport ATPases, are integral membrane proteins. They have binding sites for ATP located on the membrane's cytosolic side and the ion-conducting domain in the transmembrane region. These pumps use the free energy released from ATP hydrolysis to move the solutes across cell membranes against an electrochemical gradient.
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
9.8K
02:34Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
01:28Cholinergic Antagonists: Pharmacological Actions
1.7K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.7K